We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie Pays $200 Million for Immuno-Oncology Antibody From Chinese Drugmaker
AbbVie Pays $200 Million for Immuno-Oncology Antibody From Chinese Drugmaker
AbbVie has signed a collaboration agreement with Chinese biotech I-Mab to develop and commercialize, lemzoparlimab (TJC4), I-Mab’s monoclonal antibody under development for multiple cancers.